MERCK
Merck, a leading science and technology company, today announced a strategically focused expansion of its neurology pipeline with the acquisition of the rights to develop cladribine for the treatment of generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD). Merck entered into an agreement to secure the global rights by acquiring Chord Therapeutics, a Swiss-based biotech company focused on rare neuroinflammatory diseases.
“Cladribine has a unique mechanism of action which is relevant in antibody-mediated disease such as NMOSD and gMG. In exploratory studies, cladribine demonstrated promising results in these diseases. These data have prompted us to initiate further development with cladribine in gMG and NMOSD to potentially bring a new therapeutic option to patients and expand our portfolio in this area,” said Danny Bar-Zohar, MD, Head of Global Development for the biopharma business of Merck.
Cladribine is a well characterized molecule that has been extensively studied across MS and oncologic disorders and has shown promising results in exploratory studies in gMG and NMOSD. Merck plans to leverage its existing capabilities to further develop an oral cladribine product tailored specifically for these indications. The transaction is expected to be closed in early 2022 after satisfactory completion of customary closing conditions.
Generalized myasthenia gravis is a disease in which patients experience weakness in ocular, limb, and respiratory muscles and that has a significant impact on Quality of Life. It is estimated that 700,000 people around the world are living with gMG. NMOSD, also known as Devic´s disease, is an autoimmune disease, often misdiagnosed as MS due to similar symptoms. NMOSD is estimated to impact 200,000 people around the world.
About Chord Therapeutics
Chord Therapeutics is a Swiss-based clinical stage pharmaceutical company developing drugs for patients with rare, life-threatening and severely disabling diseases. Chord is advancing its lead drug candidate, CRD1 (cladribine), for the treatment of neuromyelitis optica spectrum disorders (NMOSD) and generalized myasthenia gravis (gMG). Chord Therapeutics was founded in 2014 and launched in October 2020 with Series A funding by its sole investor, Omega Funds, a leading international venture capital firm focused on delivering impactful medicines to patients.
Merck in Neurology and Immunology
Merck has a long-standing legacy in neurology and immunology, with significant R&D and commercial experience in multiple sclerosis (MS). The company`s current MS portfolio includes two products for the treatment of relapsing MS – Rebif® (interferon beta-1a) and MAVENCLAD® (cladribine tablets). Merck aims to improve the lives of patients by addressing areas of unmet medical needs. In addition to Merck`s commitment to MS, the company also has a pipeline focusing on discovering new therapies that have the potential in other neuroinflammatory and immune-mediated diseases, including systemic lupus erythematosus (SLE).
All Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.
About Merck
Merck, a leading science and technology company, operates across healthcare, life science and electronics. Around 58,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2020, Merck generated sales of € 17.5 billion in 66 countries.
Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Electronics.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211220005062/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Exstent Appoints Matt Thompson as CEO to Drive Global Growth in Personalised Aortic Support12.11.2025 08:04:00 CET | Press release
Exstent, a UK-based medical device company, developing personalised external aortic support to preserve the native aorta, today announced the appointment of Matt Thompson as Chief Executive Officer to lead its next phase of global growth. Matt brings more than two decades of combined clinical and commercial leadership to Exstent. He previously held leadership roles including President and CEO at Endologix, guiding the company through transformation, portfolio growth, and the 2021 acquisition of PQ Bypass. Earlier in his career, Matt was Professor of Vascular Surgery at St George’s Hospital, University of London, and Consultant Vascular Surgeon at St George’s Vascular Institute. His experience in integrating novel vascular technologies into established commercial frameworks aligns closely with Exstent’s strategic direction. “Exstent’s personalised external aortic support is a meaningful advance in managing ascending aortic disease,” said Matt Thompson, CEO of Exstent. “It preserves the
Ant International’s Antom Launches AI‑Powered MSME App for Finance and Business Operations12.11.2025 03:00:00 CET | Press release
The EPOS360 App integrates POS system, payments, banking, lending, and growth support into one platform to help MSMEs start, grow, and scale efficiently.The app embeds an AI copilot to simplify operations and turn business information into actionable insights.Supported by ANEXT Bank, one of the first digital banks in Singapore, MSMEs can access credit faster and manage financing with greater ease. Antom, a leading provider of merchant payment and digitisation services under Ant International, today announced EPOS360, an app that brings point-of-sale (POS) system, payments, banking, lending, and growth support together to help micro, small and medium-sized enterprises (MSMEs) move from setup to scale efficiently. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251111066634/en/ The AI-powered EPOS360 provides POS system, payments, banking, lending and other growth-enabling services, offering customised support to help MSMEs ope
Venture Global and Mitsui Announce 20-Year LNG Sales and Purchase Agreement12.11.2025 00:00:00 CET | Press release
Venture Global’s third long-term contract with a Japanese company6.75 MTPA of long-term contracts signed by Venture Global to date in 2025 Today, Venture Global, Inc. (NYSE: VG) and Mitsui & Co., Ltd. of Japan announced the execution of a new, long-term liquefied natural gas (LNG) Sales and Purchase Agreement (SPA). Under the SPA, Mitsui will purchase 1.0 million tonnes per annum (MTPA) of LNG from Venture Global for 20 years, starting in 2029. “Venture Global is honored to announce our new partnership with Mitsui, a distinguished leader in the LNG industry, to further increase the flow of U.S. LNG to Japan and the global market,” said Mike Sabel, CEO of Venture Global. “This collaboration between our two companies will strengthen energy security, enhance the balance of trade, and deepen the long-standing ties between our nations. This agreement builds upon our existing long-term relationships with Japanese companies, and we are deeply grateful for their continued trust in Venture Glob
Lattice to Showcase Advanced Industrial and Edge AI Solutions at SPS 202511.11.2025 22:00:00 CET | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced its participation in the upcoming SPS 2025, taking place on November 25 – 27, 2025 in Nuremberg, Germany. Lattice will deliver a presentation on secure motor control solutions and technology demonstrations with industry partners focused on advanced embedded vision and machine learning applications for the Industrial market. Who: Lattice Semiconductor What / When (GMT+2):Nov. 25 – 27, 2025: Embedded Vision and Machine Learning Demo Showcase EtherCAT Technology Group Booth (Hall 5, #310) Exor booth (Hall 9, #375) Nov. 25, 2025: Tech Talk (11 – 11:30 a.m.) Secure Connected Motion Control Platform for AC Motors: A Collaborative Innovation by Analog Devices and Lattice Semiconductor Where: Nuremberg Messe, Nuremberg, Germany SPS (Smart Product Solution) 2025 is one of the world’s leading trade fairs for industrial automation and digitalization. It showcases the entire spectrum of smart and digital autom
TOURISE Announces USD 113BN in Portfolio Investments to Accelerate the Future of Tourism11.11.2025 18:42:00 CET | Press release
High‑impact dealmaking at the inaugural TOURISE Summit catalyzes cross‑sector capital for growth across the global tourism ecosystem. TOURISE, the bold global platform shaping a new horizon for tourism, announced today that it has catalyzed investment portfolios totaling USD 113BN at the inaugural TOURISE Summit in Riyadh. The milestone reflects TOURISE’s mission to unlock high‑value deal flow by convening public and private sector leaders across tourism, technology, investment, and sustainability to set a shared roadmap for the next 50 years of global tourism. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251111666032/en/ His Excellency Ahmed Al Khateeb, Saudi Arabia's Minister of Tourism and Chairman of TOURISE announces USD 113 BN of investment portfolios catalyzed at the inaugural TOURISE Summit. The announced portfolio investments span the full breadth of the visitor economy: luxury retail, next‑generation hotel accomm
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom